• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

    73.91 -0.49 (-0.66%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,639,043
    Open 74.29
    Bid (Size) 74.00 (500)
    Ask (Size) 75.75 (200)
    Prev. Close 74.40
    Today's Range 73.26 - 75.31
    52wk Range 12.44 - 76.76
    Shares Outstanding 105,736,200
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire

    Performance

    YTD
    +9.0%
    +9.0%
    1 Month
    +21.6%
    +21.6%
    3 Month
    +10.2%
    +10.2%
    6 Month
    +94.5%
    +94.5%
    1 Year
    +454.0%
    +454.0%

    More News

    Read More
    News headline image
    Arrowhead Pharmaceuticals (NASDAQ:ARWR) Emerges as a Growth Stock with a Constructive Technical Setup ↗
    Via Chartmill
    Arrowhead Pharmaceuticals (NASDAQ:ARWR) Presents a High-Growth, Technical Breakout Opportunity ↗
    Via Chartmill
    Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reports Profitable Quarter on Strong Drug Launch ↗
    Via Chartmill
    News headline image
    Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Sarepta's RNA Renaissance: 35% Surge as siRNA Breakthrough Silences Skeptics
    Via MarketMinute
    News headline image
    Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data
    Via MarketMinute
    News headline image
    Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    The Great Rotation: How the 'One Big Beautiful Bill Act' is Igniting a Small-Cap Renaissance
    Via MarketMinute
    Topics Artificial Intelligence Economy Government
    News headline image
    Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
    From BioMedWire
    Via GlobeNewswire
    News headline image
    Arrowhead (ARWR) Q1 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ciena’s AI-Driven Return: Networking Giant to Join S&P 500 Benchmark
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    News headline image
    Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    Is Arrowhead Pharmaceuticals Stock a Buy or Sell After the CEO Sold Shares Worth $5.4 Million? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Nvidia’s $5 Trillion Peak Sparks Massive Nasdaq Retreat as Investors Pivot to Value
    Via MarketMinute
    Topics Artificial Intelligence Economy Stocks
    News headline image
    Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    The Great Rotation: Small-Caps Lead 2026 Market Charge as Tech Giants Stumble
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    News headline image
    Why Did ARWR Stock Surge Over 15% Pre-Market Today? ↗
    Via Stocktwits

    Frequently Asked Questions

    Is Arrowhead Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Arrowhead Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Arrowhead Pharmaceuticals, Inc. - Common Stock trade on?
    Arrowhead Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Arrowhead Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Arrowhead Pharmaceuticals, Inc. - Common Stock is ARWR on the Nasdaq Stock Market
    What is the current price of Arrowhead Pharmaceuticals, Inc. - Common Stock?
    The current price of Arrowhead Pharmaceuticals, Inc. - Common Stock is 73.91
    When was Arrowhead Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Arrowhead Pharmaceuticals, Inc. - Common Stock was at 04/24/26 04:00 PM ET
    What is the market capitalization of Arrowhead Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Arrowhead Pharmaceuticals, Inc. - Common Stock is 7.81B
    How many shares of Arrowhead Pharmaceuticals, Inc. - Common Stock are outstanding?
    Arrowhead Pharmaceuticals, Inc. - Common Stock has 8B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.